Contraindicated in:
Use Cautiously in:
CV: edema, HF, hypertension, MI.
Derm: rash.
EENT: blurred vision, tinnitus.
Endo: IV: hypoglycemia.
F and E: hyperkalemia.
IV: dilutional hyponatremia.
GI: constipation, dyspepsia, nausea, vomiting, discomfort.
PO: GI BLEEDING, HEPATOTOXICITY, necrotizing enterocolitis, PANCREATITIS.
GU: cystitis, hematuria, renal failure.
Hemat: blood dyscrasias, prolonged bleeding time, thrombocytopenia.
Local: phlebitis at IV site.
Neuro: dizziness, drowsiness, headache, psychic disturbances, STROKE.
Drug-Drug:
Drug-Natural Products:
(Generic available)
Anti-inflammatory
PDA Closure
Indocin, Tivorbex
Therapeutic Classification: antirheumatics, ductus arteriosus patency adjuncts (IV only), nonopioid analgesics
Pharmacologic Classification:
Absorption: Well absorbed after oral administration in adults, incomplete oral absorption in neonates.
Distribution: Crosses the blood-brain barrier.
Protein Binding: 99%.
Metabolism/Excretion: Mostly metabolized by the liver.
Half-life: Neonates <2 wk: 20 hr; Neonates >2 wk: 11 hr; Adults: 2.611 hr.
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO (analgesic) | 30 min | 0.52 hr | 46 hr |
PO-ER (analgesic) | 30 min | unknown | 46 hr |
PO (anti-inflammatory) | up to 7 days | 12 wk | 46 hr |
PO-ER (anti-inflammatory) | up to 7 days | 12 wk | 46 hr |
IV (closure of PDA) | up to 48 hr | unknown | unknown |
NDC Code*